How to Store SS 31: Stability and Handling, Per the Research

What the literature does — and does not — cover

SS 31, also written SS-31 and known in the clinical literature as elamipretide, Bendavia and MTP-131, is a short cationic tetrapeptide studied for its association with the inner mitochondrial membrane lipid cardiolipin. The published record on this compound is overwhelmingly pharmacological: researchers described what happened in cells, tissues and animals after exposure, not how the material behaved on a shelf.

That distinction matters for a storage page. In the verified literature summarised here, a 2026 study in the Journal of Ovarian Research reported that SS-31 improved the quality of maternally aged oocytes by ameliorating mitochondrial function and metabolism (PMID 41612464), and a 2021 paper in Free Radical Research reported that SS-31 attenuated lipopolysaccharide-induced apoptosis and pyroptosis of nucleus pulposus cells by scavenging mitochondrial reactive oxygen species and maintaining the stability of mitochondrial dynamics (PMID 34903138). Neither of those papers, nor the others cited below, presented accelerated-stability testing, freeze–thaw cycling data or shelf-life dating for SS 31.

So the honest framing is this: compound-specific stability data for SS 31 is not present in the verified citation set on this page. Statements below about lyophilized powder, reconstituted solutions, temperature excursions and visual degradation cues are drawn from general peptide-chemistry principles that apply to short synthetic peptides as a class, and they are explicitly labelled as general each time. They are not findings about SS 31 in particular.

This page is for educational purposes only and is not medical advice; consult a licensed physician for any health decision. Nothing here is a protocol, an instruction or a handling recommendation.

Lyophilized powder versus material in solution

Lyophilization (freeze-drying) is the standard way short synthetic peptides are shipped and stored. As a general principle of peptide chemistry rather than an SS 31-specific finding, removing water from a peptide slows the hydrolytic and oxidative reactions that need a liquid phase to proceed. A lyophilized cake sitting under vacuum or inert gas in a sealed vial is, in general terms, the most chemically quiet state the molecule occupies.

Once a peptide is dissolved, the chemistry restarts. General formulation science describes several routes by which peptides in aqueous solution lose intact parent compound over time: hydrolysis of amide bonds, oxidation of susceptible side chains, adsorption of the peptide onto container surfaces, aggregation, and — if the solution is not preserved — microbial growth that introduces enzymes and changes pH. SS 31's published sequence includes aromatic and basic residues and a C-terminal amide; residues of those classes are, in general peptide-stability literature, the ones most often discussed as oxidation- and hydrolysis-sensitive. Again, that is a class-level statement, not a measured SS 31 result.

One indirect signal that formulation matters for this compound comes from the delivery-vehicle literature. A 2025 paper in ACS Applied Materials & Interfaces described a polyphosphate- and antioxidant peptide-based coacervate used to deliver miRNA (PMID 40478241), and a separate 2025 paper in the same journal described functionalized nanoparticles used to target AGO-2 to myocardial mitochondria and attenuate oxidative stress in diabetic cardiomyopathy (PMID 41288605). Researchers built carriers in both cases rather than relying on a bare peptide in buffer, which illustrates how much of this field's methodology is formulation-dependent — though neither study reported storage or stability endpoints.

Refrigeration: what the general stability science describes

Lyophilized material

General practice in peptide laboratories, as described in handling literature for synthetic peptides broadly, is that sealed lyophilized powder is held cold and dry, with desiccation treated as equally important as temperature. Two recurring themes in that general literature are: (1) moisture ingress is a larger practical threat to a freeze-dried cake than a modest temperature rise, and (2) condensation forms when a cold sealed vial is opened in warm room air, which is why general protocols describe equilibrating vials to ambient temperature before the seal is broken. Neither point derives from an SS 31 study.

Material in solution

General peptide-stability science treats refrigeration of aqueous peptide solutions as a way to slow, not stop, degradation. Reaction rates for hydrolysis and oxidation fall with temperature, so solutions held near 2–8 °C are generally described as degrading more slowly than the same solution at room temperature — but the clock still runs. Published SS 31 pharmacology papers worked with freshly prepared working solutions in defined media; for example, a 2017 study examined Bendavia (SS-31) against oxygen/glucose-deprivation stress-induced mitochondrial damage in human brain microvascular endothelial cells (PMID 27855593), and a 2018 study reported that mitoprotective therapy preserved chondrocyte viability and prevented cartilage degeneration in an ex vivo model of posttraumatic osteoarthritis (PMID 29469223). Those papers described experimental designs, not solution shelf life.

Shelf life, expiry and what a certificate of analysis actually says

Research-grade peptide material is typically distributed with a certificate of analysis that reports identity (usually by mass spectrometry) and purity (usually by reversed-phase HPLC) at the time of manufacture. As a general point about analytical documentation rather than a finding about SS 31, a purity figure on a certificate is a snapshot, not a guarantee of future content, and a "best before" or "retest" date assigned by a supplier is not the same thing as a regulator-reviewed expiry date supported by stability data under ICH-style testing.

The verified literature on SS 31 does not include shelf-life dating. Papers such as the 2024 European Journal of Pharmacology analysis of cardiolipin degradation and disturbed linoleic acid metabolism in cardiac atrophy under cancer cachexia (PMID 39515561) and the 2020 Oncotarget study reporting that pharmacological targeting of mitochondrial function and reactive oxygen species production prevented colon 26 cancer-induced cardiorespiratory muscle weakness (PMID 33014286) described biological outcomes; neither reported how long stored material remained within specification.

Room temperature, shipping and travel excursions

Short excursions above refrigeration are a routine reality of shipping, and general lyophilized-peptide science addresses them directly: a dry, sealed cake is far more tolerant of a warm transit leg than the same peptide in solution, because the principal degradation pathways are water-dependent. This is why cold-chain literature for freeze-dried biologics generally treats cumulative time-at-temperature, not a single threshold crossing, as the meaningful variable. None of these statements is an SS 31 measurement.

General handling science also notes that repeated warm/cool cycling — the pattern created by a vial moving in and out of a refrigerator, a cooler bag and a car — tends to be harder on formulations than a single stable holding temperature, partly because cycling drives moisture movement inside a sealed container. Travel documentation, customs status and the research-use-only labelling that accompanies non-approved material are regulatory matters separate from chemistry, and they vary by jurisdiction.

Freezing and freeze–thaw

For lyophilized powder, general peptide-storage practice describes long-term holding at freezer temperatures for material not in active use, with desiccation maintained. For solutions, the general literature describes a trade-off: freezing arrests most solution-phase chemistry, but each freeze–thaw cycle concentrates solutes at the ice interface, can shift local pH as buffer components crystallize at different rates, and introduces mechanical stress that promotes aggregation in some peptides. The general mitigation described in formulation texts is single-use aliquoting so that a given volume is thawed once rather than cycled repeatedly. No freeze–thaw data for SS 31 appears in the verified papers on this page.

Light, containers and adsorption

General peptide-handling science highlights three container-level variables that are easy to overlook. First, photodegradation: peptides containing aromatic residues are, as a class, discussed as light-sensitive, which is why amber or foil-protected vials are standard in general practice. Second, surface adsorption: dilute peptide solutions can lose measurable material to glass and plastic surfaces, a general phenomenon that matters most at low concentrations. Third, closure integrity: an elastomeric stopper that has been punctured repeatedly no longer provides the same barrier, a general point about sterile-container science rather than an SS 31 finding.

Signs of degradation described in general peptide science

The general literature distinguishes between what is visible and what is measurable.

• Visible cues (non-specific): a collapsed, shrunken or melted-looking cake; discoloration of powder or solution; visible particulates, haze or fibres in a previously clear solution; a cake that has partially liquefied, which general practice associates with moisture ingress.
• Measurable cues (analytical): loss of parent peak area and appearance of new peaks on reversed-phase HPLC; mass shifts on mass spectrometry consistent with oxidation or hydrolysis; changes in pH; increases in subvisible particle counts.

The critical general caveat is that a peptide can degrade substantially with no visible change at all, and conversely that a normal-looking cake carries no analytical information. Appearance is a screening cue in general laboratory practice, not a purity assay.

Storage variables at a glance

Why the pharmacology literature still matters here

Storage questions exist because the material is expected to behave consistently between preparation and use. In the SS 31 literature, that consistency is assumed rather than tested: a 2026 study in Brain, Behavior, and Immunity reported that disruption of hippocampal mitochondrial function underlay opioid-induced postoperative cognitive dysfunction in aged rats (PMID 42546889), with the corresponding preprint archived separately (PMID 41676478), and a 2023 ACS Central Science paper described a triple-targeted rutin-based self-assembled delivery vector for ischemic stroke acting via ACE2/Ang1-7 signalling (PMID 37396868). A 2025 scoping review in the Journal of Cachexia, Sarcopenia and Muscle surveyed the role of peptides in skeletal muscle wasting (PMID 41231146). Across that body of work, researchers reported biological endpoints; none of it substitutes for formal stability testing, and readers evaluating storage claims about SS 31 should be aware that such claims are generally extrapolated from peptide chemistry as a class.

References

• SS-31 improves the quality of maternally aged oocytes by ameliorating mitochondrial function and metabolism (Journal of Ovarian Research, 2026)
• The mitochondrial antioxidant SS-31 attenuated lipopolysaccharide-induced apoptosis and pyroptosis of nucleus pulposus cells via scavenging mitochondrial ROS and maintaining the stability of mitochondrial dynamics (Free Radical Research, 2021)
• Protective Effect of Bendavia (SS-31) Against Oxygen/Glucose-Deprivation Stress-Induced Mitochondrial Damage in Human Brain Microvascular Endothelial Cells (Current Neurovascular Research, 2017)
• Mitoprotective therapy preserves chondrocyte viability and prevents cartilage degeneration in an ex vivo model of posttraumatic osteoarthritis (Journal of Orthopaedic Research, 2018)
• The involvement and possible targeting of cardiolipins degradation and disturbed linoleic acid metabolism in cardiac atrophy under cancer cachexia (European Journal of Pharmacology, 2024)
• Pharmacological targeting of mitochondrial function and reactive oxygen species production prevents colon 26 cancer-induced cardiorespiratory muscle weakness (Oncotarget, 2020)
• Targeted Delivery of AGO-2 to Myocardial Mitochondria via Functionalized Nanoparticles Attenuates Oxidative Stress in Diabetic Cardiomyopathy (ACS Applied Materials & Interfaces, 2025)
• Polyphosphate- and Antioxidant Peptide-Based Coacervate Delivers miRNA (ACS Applied Materials & Interfaces, 2025)
• A Triple-Targeted Rutin-Based Self-Assembled Delivery Vector for Treating Ischemic Stroke by Vascular Normalization and Anti-Inflammation via ACE2/Ang1-7 Signaling (ACS Central Science, 2023)
• Disruption of hippocampal mitochondrial function underlies opioid-induced postoperative cognitive dysfunction in aged rats (Brain, Behavior, and Immunity, 2026)
• Disruption of hippocampal mitochondrial function underlies opioid-induced postoperative cognitive dysfunction in aged rats (bioRxiv, 2026)
• Role of Peptides in Skeletal Muscle Wasting: A Scoping Review (Journal of Cachexia, Sarcopenia and Muscle, 2025)